Kyn, Arrys raise series A rounds from Atlas, OrbiMed

Immuno-oncology companies Kyn Therapeutics Inc. (Cambridge, Mass.) and Arrys Therapeutics Inc. (Cambridge, Mass.) announced a collective $49 million in series A funding from Atlas Venture and OrbiMed Advisors.

Arrys raised $21 million, while Kyn disclosed a $28 million series A round, which it raised last year. Kyn President and CEO Mark Manfredi declined to disclose whether the rounds are tranched. ...